Over the past few years, cell and gene therapies have gained significant popularity owing to their therapeutic potential.

In fact, more than 20 genetically modified therapies have already been approved, which has resulted in the increase in demand for vectors, which have proven to be highly efficient for the delivery of genetic material to the targeted area. In order to cater to the growing demand, several companies are offering diverse range of services for vector and gene therapy manufacturing. 

By 2035, the financial opportunity within the viral vector manufacturing, non-viral vector manufacturing and gene therapy manufacturing market has been analyzed across the following segments:

§  Scale of Operation

• Lab
• Clinical
• Commercial

§  Type of Vectors

• AAV
• Adenoviral
• Lentiviral
• Retroviral
• Plasmid DNA
• Other Vectors

§  Application Area

• Gene Therapy
• Cell Therapy
• Vaccines

§  Therapeutic Area

§  Oncological Disorders

§  Rare Disorders

§  Neurological Disorders

§  Sensory Disorders

§  Metabolic Disorders

§  Musco-skeletal Disorders

§  Blood Disorders

§  Immunological Diseases

§  Others

§  Geographical Regions

• North America
• Europe
• Asia Pacific
• Latin America
• MENA
• Rest of the World

The “Viral Vector, Non-Viral Vector and Gene Therapy Manufacturing Market (5^th Edition), 2022-2035” report features the following companies, which we identified to be key players in this domain:

§  Advanced BioScience Laboratories

§  Aldevron

§  Audentes Therapeutics

§  BioNTech Innovative Manufacturing

§  BioReliance

§  Biovian

§  bluebird bio

§  Cell and Gene Therapy Catapult

§  Celonic

§  Centre for Process Innovation

§  Cobra Biologics

§  Emergent BioSolutions

§  FinVector

§  FUJIFILM Diosynth Biotechnologies

§  Kaneka Eurogentec

§  Lonza

§  MeiraGTx

§  MolMed

§  Novasep

§  Orchard Therapeutics

§  Oxford BioMedica

§  Richter-Helm

§  Sanofi

§  Spark Therapeutics

§  Thermo Fisher Scientific

§  uniQure

§  Vibalogics

§  Vigene Biosciences

§  VIVEbiotech

§  Wuxi AppTech

Table of Contents

1.      Preface

2.      Executive Summary

3.      Introduction

4.      Viral Vector and Gene Therapy Manufacturers (Industry Players): Market Landscape

1.     Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Market Landscape

2.     Vector And Gene Therapy Manufacturers (Non-Industry Players): Market Landscape

3.     Vector And Gene Therapy Manufacturing Technologies: Market Landscape

4.     Company Competitiveness Analysis

5.     Vector And Gene Therapy Manufacturers in North America

6.     Vector And Gene Therapy Manufacturers in Europe

7.     Vector And Gene Therapy Manufacturers in Asia-Pacific

8.      Other Key Players

9.     Recent Partnerships

14. Recent Expansions

15.             Strategic Partner Analysis

16. Emerging Vectors

17. Key Insights

18. Cost Price Analysis

19. Capacity Analysis

20.             Demand Analysis

• #Viral_Vector_Manufacturing_Market
• #Gene_therapy_Manufacturing
• #Vector_Manufacturing
• #Vector_manufacturing_market
• #Non-Viral_vector_Manufacturing_Market